Trump Adds Nine Drugmakers to Pharma Pricing Deal, Easing Overhang for Bitcoin (BTC)

Nine New Agreements

President Trump added nine more pharmaceutical manufacturers to his drug-pricing framework at a White House event on Monday, widening a program that has quietly become one of the administration's most consistent policy signatures. The new signatories are mostly midsize drugmakers — among them Alcon, Astellas Pharma and Teva Pharmaceuticals — and together they committed $19.6 billion toward U.S. manufacturing, according to the official White House fact sheet released alongside the announcement. The companies also agreed to offer their medicines to every state Medicaid program at discounted prices, extending the framework's reach beyond the federal channels it originally targeted. Teva's inclusion is notable given its generics-heavy portfolio — a reminder that the program now spans branded and off-patent producers alike. The White House says 17 companies had already joined the pricing framework over the past year; the latest round brings the total to 26 firms that, on the administration's math, represent roughly 90% of the domestic pharmaceutical market. Trump cast the expansion in blunt terms, noting the remaining 10% of the market is “also coming in” and adding: “They have no choice.” The administration puts combined savings from the deals struck over the past year at more than $600 billion for American consumers. The announcement lands against a strong market backdrop: healthcare equities just closed their best quarter to date, and the pricing push — once feared as an open-ended sector crackdown — is increasingly read by investors as a settled, bounded risk. What was not disclosed matters too: the fact sheet does not itemize per-drug price levels, rebate mechanics or enforcement timelines, leaving the market to price the program on its headline commitments alone.

UBS Sees the Rally Extending

The institutional read has followed quickly. Michael Yee, UBS's global head of biotechnology equity research, argues the advance reflects a stack of major clinical wins rather than a policy trade alone — and that the new pricing agreements have proven less onerous than feared, removing what he describes as a major source of uncertainty for the sector. The tape supports that view: the SPDR S&P Biotech ETF (XBI), the benchmark for the biotech complex, is up 80% in twelve months, outpacing most other equity groups — a breadth profile closer to small-cap risk benchmarks like the Russell 2000 ETF (IWM) than to any narrow defensive rotation. Yee's top picks underline the fundamental driver behind the move. Merck's melanoma vaccine, developed with Moderna, met its primary trial goals in a study of more than 1,100 patients, with results reported on August 19. He also flagged Merck's antibody-drug conjugate sacituzumab tirumotecan, which posted a positive lung-cancer readout earlier this year and is now being tested across 17 late-stage studies. Revolution Medicines is another highlighted name: the FDA approved its pancreatic cancer therapy daraxonrasib on August 26, and the drug nearly doubled median survival versus chemotherapy in a late-stage trial. Bristol Myers Squibb completes the list — UBS carries a Buy rating there and expects several late-stage readouts before year-end, catalysts that could offset revenue lost to patent expirations. Yee's broader thesis is that drugmakers are sitting on record cash piles, pushing more of it into R&D after a multiyear stretch of cheap valuations, with valuations still not stretched and Washington's pricing overhang easing. The current move, in his framing, looks like the start of a longer re-rating rather than a short-lived bounce. Readers tracking the market in real time can follow live spot and futures prices on Gate.

Macro Read-Through for Bitcoin

For digital assets, the signal matters more than the sector. Another policy overhang clearing in Washington is the same macro-clarity dynamic that keeps risk assets bid — the regime in which crypto-linked equities such as Coinbase Global (COIN) shares and high-beta tech from Micron Technology (MU) to Netflix (NFLX) tend to lead. Our live market snapshot shows Bitcoin (BTC) holding near $78,362 with Ethereum (ETH) at $2,461 at the time of writing — consolidation rather than conviction, but consistent with an equity-led re-rating that has begun to spill into the DeFi sector. The deal's headline terms are confirmed; any crypto-specific flow impact remains undisclosed.